- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Intradigm Corporation, a leading developer of targeted and effective RNA interference (RNAi)
therapeutics, today announced the appointment of Samuel Zalipsky, Ph.D., as vice president, technology development. Dr. Zalipsky brings more than 20 years of experience in the pharmaceutical and biotechnology industry and offers significant expertise in areas critical to Intradigm's growth.
Dr. Zalipsky comes to Intradigm following an eight-year tenure with
ALZA Corporation, a member of the Johnson & Johnson family of companies,
during which he established himself as a leading expert on drug delivery
systems. His broad drug delivery expertise spans several important areas
including chemistry of peptides, polymers for bio-medical application,
bioconjugates with drugs, peptides/proteins, saccharides, lipids/liposomes,
and nanoparticles. He is widely regarded as an active researcher and
inventor, particularly in the areas of macromolecular and nanoparticular
At ALZA, Dr. Zalipsky established and managed programs focused on
delivery of biopharmaceuticals, PEGylated proteins, and targeted delivery
of liposomes. Prior to his work with ALZA, he held key scientific positions
with SEQUUS Pharmaceuticals and Enzon Inc., while also serving as a
visiting associate professor in the chemistry department of Rutgers
University. In his new role, Dr. Zalipsky will spearhead the continued
development of Intradigm's proprietary nanoparticle-based RNAi delivery
technology, as well as its novel RNAi therapeutic formulations. He will
also be responsible for overseeing the company's work in the areas of new
technology development and new technology in-licensing.
"While Samuel possesses impressive experience in the biotechnology and
pharmaceutical industry, it is the relevance of his expertise as it relates
to Intradigm's RNAi drug delivery focus that makes him such an ideal
addition to our team," said Mohammad Azab, M.D., president and chief
executive officer of Intradigm. "We are very happy to welcome Samuel to
Intradigm and look forward to the critical contributions he will make to
the company and our efforts to bring innovative RNAi therapeutics to the
About Intradigm Corporation
Intradigm is a private biotechnology company dedicated to the
development of targeted and effective RNA interference (RNAi) therapeutics
for the treatment of serious diseases with an initial focus on oncology.
The company's expertise in the development and delivery of RNAi molecules
serves as the foundation of Intradigm's drug development platform. In
particular, the company's novel and proprietary RNAi Nanoplex(TM) delivery
technology is unique in its ability to allow the targeted delivery of RNAi
therapeutics to specific tissues though systemic administration.
At present, Intradigm is working to build a high-value internal
pipeline of RNAi oncology therapeutics, and is actively advancing its lead
internal drug candidate, ICS-283, for a variety of cancer indications. The
company is also establishing collaborative relationships with
pharmaceutical and biotechnology companies through which Intradigm's
advanced RNAi delivery technology may be applied to a broad range of therapeutic targets.
For more information, please click here
3350 W Bayshore Rd, Suite 100;
Palo Alto, CA 94303
Phone: (650) 855 9696
Fax: (650) 855 9699
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
In-cell molecular sieve from protein crystal February 14th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017
Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017
Engineers shrink microscope to dime-sized device February 17th, 2017